View Older Stories View More Recent Stories

Apr 30, 2019 12:15PM Renewable electricity to completely power Novo Nordisk US operations in early 2020
Apr 12, 2019 06:31AM Gilead Sciences (GILD), Novo Nordisk (NVO) Announce Intent to Initiate a Clinical Collaboration in NASH
Mar 1, 2019 07:00AM Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents
Sep 12, 2018 06:00AM EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
Sep 10, 2018 07:03AM EyePoint Pharmaceuticals (EYPT) Reports Election of Goran Ando M.D. as Next Board Chairman
Sep 10, 2018 07:00AM EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
Jun 26, 2018 07:00AM EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors
Apr 26, 2018 08:30AM Emisphere Amends License Agreement with Novo Nordisk
Apr 26, 2018 08:30AM Emisphere Amends License Agreement with Novo Nordisk
Jan 8, 2018 07:28AM Ablynx NV (ABLX) Says Novo Nordisk (NVO) Offer Undervalues Company
Jan 8, 2018 07:26AM ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS
Jan 8, 2018 07:25AM ABLYNX STRONGLY BELIEVES UNSOLICITED CONDITIONAL PROPOSAL FROM NOVO NORDISK FUNDAMENTALLY UNDERVALUES THE COMPANY AND ITS FUTURE PROSPECTS
Nov 8, 2017 11:14AM "Diabetes 360" Survey Shows Patients Want More Than Medicine, Need Emotional Support
Oct 26, 2017 02:00AM Global City Leaders: Cut Obesity By A Quarter To Prevent 100M New Diabetes Cases By 2045
Oct 18, 2017 05:34PM Novo Nordisk receives positive 16-0 vote from FDA Advisory Committee in favor of approval for semaglutide
Sep 29, 2017 11:03AM Novo Nordisk Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime Insulin
Sep 26, 2017 12:51PM Working Mother names Novo Nordisk one of its "100 Best Companies"
Sep 5, 2017 05:14PM Novo Nordisk (NVO) Confirms Settlement with U.S. Gov. Related to Marketing Practices for Victoza
Sep 5, 2017 05:10PM Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices
Aug 25, 2017 12:24PM Novo Nordisk' (NVO) Says Victoza Approved in US as Type 2 Diabetes Treatment Indicated to Reduce Risk of Three Cardiovascular Events
Aug 25, 2017 12:18PM Victoza® (liraglutide) is approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of three major adverse cardiovascular events
Jul 12, 2017 11:05AM Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management
Jul 5, 2017 03:37PM Novo Nordisk (NVO) Announces Recall of Cartridge Holders in Certain NovoPen Echo Insulin Delivery Devices Citing Potential Health Risks
Jul 5, 2017 03:30PM Novo Nordisk recalls cartridge holders in certain NovoPen Echo® insulin delivery devices due to potential health risks
May 31, 2017 05:32PM FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia
May 3, 2017 10:15AM Novo Nordisk Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in the United States
Apr 17, 2017 09:33AM Novo Nordisk Invites the Community to Unmask Everyday Heroes in Recognition of World Hemophilia Day
Mar 9, 2017 09:04AM Novo Nordisk Named on the FORTUNE 100 Best Companies to Work For® List for Ninth Consecutive Year
Feb 9, 2017 09:33AM Great Place to Work® and Fortune Name Novo Nordisk as one of the country's best workplaces for giving back
Dec 20, 2016 05:25PM Fluor (FLR) Awarded Contract to Build $2B Diabetes API Manufacturing Facility for Novo Nordisk (NVO)
Dec 5, 2016 09:44AM Novo Nordisk (NVO) Files Semaglutide NDA with U.S. FDA as T2D Treatment
Dec 5, 2016 09:42AM Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes
Nov 14, 2016 08:05AM One World Trade Center to Glow Blue in Honor of World Diabetes Day Tonight
Nov 3, 2016 07:00AM New study showed that only 55% of people with obesity have received a formal obesity diagnosis
Oct 27, 2016 09:00AM Novo Nordisk to present eight abstracts at the 4th annual ObesityWeek in New Orleans, LA
Sep 27, 2016 12:48PM Working Mother names Novo Nordisk Inc. one of its "100 Best Companies"
Sep 15, 2016 12:37PM Great Place to Work® and Fortune name Novo Nordisk as one of the country's best workplaces for women
Sep 8, 2016 02:16PM Novo Nordisk Inc. issues voluntary nationwide recall of six batches of GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) due to detached needles on the syringe in the kit
Sep 8, 2016 02:16PM Novo Nordisk Inc. issues voluntary nationwide recall of six batches of GlucaGen® HypoKit® (glucagon [rDNA origin] for injection) due to detached needles on the syringe in the kit
Apr 4, 2016 10:00AM Saxenda® (liraglutide [rDNA origin] injection) Demonstrated Significant Improvements in Cardiometabolic Risk Factors Over Three Years Compared With Placebo
Apr 2, 2016 01:15PM Victoza® (liraglutide [rDNA origin] injection) Provided Superior HbA1c Reductions in Adults With Type 2 Diabetes Compared to Continued Sitagliptin Treatment
Apr 2, 2016 11:45AM Semaglutide Demonstrated Superior Improvements in Glycemic Control vs Placebo in Adults with Type 2 Diabetes
Nov 13, 2015 04:27PM One World Trade Center to Glow Blue in Honor of World Diabetes Day on November 14, 2015
Nov 4, 2015 12:30PM New study finds that many people with obesity consider themselves healthy despite having obesity-related comorbidities
Nov 4, 2015 12:30PM Data presented at ObesityWeek showed Saxenda® (liraglutide [rDNA origin] injection) treatment demonstrated significant and sustained weight loss over three years compared with placebo
Oct 15, 2015 08:21AM Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement
Oct 15, 2015 08:21AM Emisphere Signs License Agreement With Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications and Amends GLP-1 Agreement
Sep 29, 2015 10:00AM Novo Nordisk Launches New Medical Resource for People Living with Hemophilia and Other Rare Bleeding Disorders
May 15, 2015 12:10PM New analysis of data in adults with obesity or who are overweight with weight-related comorbidities showed early response to Saxenda® (liraglutide [rDNA origin] injection) predicted greater weight lo
Apr 22, 2015 09:00AM Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States
View More Recent Stories View Older Stories